Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELIRI (irinotecan liposome) plus bevacizumab for metastatic colorectal cancer
ChiCTR2500110035Phase 2Completed
- Sponsor
- Tianjin People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma, sponsored by Tianjin People's Hospital. Primary endpoint: Progression-free survival. Started Sep 2025; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500110035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110035.